
Medical Oncologist-Internal Medicine. Tweets are my own. Entre #Tamaulipas & #NL #Mexico #Altruista #HereditaryCancer #cancerdusein #RareDisease #DH #DFI
Desplazamiento Forzado Interno
Joined May 2016
- Tweets16.4K
- Following3.7K
- Followers1.2K
- Likes19.5K
Pinned Tweet
Hoy ingresaron a mi domicilio con violencia. Desde Mayo/2020 tengo #amenazas de muerte. Ya había denunciado ante la @FGR_Tamps sede #NuevoLaredo y @FGJ_Tam . Mi vida y la de mi familia siguen en riesgo. @CEAVmex @CNDH @inmujeres @CONAVIM_MX @Carmenliliacrv #Tamaulipas
Kristel Gonzalez retweeted
Estimados todos, les mando saludos cordiales y les recuerdo nuestra próxima sesión del miércoles 20.00hrs.Bolivia, es ya la que corresponde a la clausura. @SLAPpatologia
Kristel Gonzalez retweeted
Senseless bureaucracy from a friend.
Respiratory fit test (“protects”from respiratory illnesses like TB) mandatory for physicians by end July (together with 30 minute course) . But also repeated in birth month, which is September for colleague. Rules are rules @HemeAaron42296
Kristel Gonzalez retweeted
Completely agree, & c/w
"#Universal #Germline #GeneticTesting for Hereditary #Cancer Syndromes in #Patients With Solid Tumor Cancer" ascopubs.org/doi/10.1200/PO.… @JCOPO_ASCO
#access #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention
Every cancer patient deserves a diagnosis
Providing links. as requested.
2016 AMA journal paper:
pubmed.ncbi.nlm.nih.gov/2707…
2023 ASCO journal paper
pubmed.ncbi.nlm.nih.gov/3693…
@VivekSubbiah
Kristel Gonzalez retweeted
Hola a todos. Les dejo la información de la sesión SLAP del próximo miércoles 9 de julio, nos vemos pronto.@SLAPpatologia
Kristel Gonzalez retweeted
First evidence that AGBL5 variants cause retinitis pigmentosa with hearing loss, suggesting a syndromic form.
nature.com/articles/s41431-0…
Kristel Gonzalez retweeted
Read a summary of "Guidelines for performing ultrasound-guided vascular cannulation: Recommendations of the American Society of Echocardiography," in the June 2025 Science, Medicine, and the Anesthesiologist: ow.ly/Rn8F50Wjh2a
Kristel Gonzalez retweeted
Every cancer patient deserves a diagnosis
Providing links. as requested.
2016 AMA journal paper:
pubmed.ncbi.nlm.nih.gov/2707…
2023 ASCO journal paper
pubmed.ncbi.nlm.nih.gov/3693…
@VivekSubbiah
Kristel Gonzalez retweeted
Today, FDA provided important updates on the risk of myocarditis after receiving an mRNA COVID-19 vaccine, noting the risk is higher in young men.
Kristel Gonzalez retweeted
The Somatic Mosaicism across Human Tissues Network | Nature nature.com/articles/s41586-0…
Kristel Gonzalez retweeted
Wonderful time, beautiful place but above all, extraordinary people !!! 🙂
Wonderful faculty dinner last night! 🙏🏻 @myESMO @KarynAGoodman @Betzabe100 @ben_irit @RachelRiechelm2 @LizzySmyth1 @MacarullaTeresa @Juanmaoconnor and so many others! #ESMOGI25 #ESMOAmbassadors #cancer #CancerResearch
Kristel Gonzalez retweeted
Dr Grewal did a wonderful job going ver this critical new target
MUC1/CA27.29;CA15.3
nature.com/articles/s41698-0…
🚀 Excited to share our new review in @Nature_NPJ Precision Oncology: “Mucin-1: A Promising Pan-Cancer Therapeutic Target”
nature.com/articles/s41698-0…
We discuss:
✅ How aberrant MUC1 expression and glycosylation drive oncogenesis in solid and hematologic cancers
✅ The pipeline of MUC1-targeted therapies — including vaccines, CAR-T cells, ADCs, radiopharmaceuticals, and bispecifics
✅ Key challenges with first-generation agents and what’s ahead for MUC1.
Thank you Dr. @Dr_R_Kurzrock for your mentorship and guidance in helping bring this work to life.
Kristel Gonzalez retweeted
¿Quieres actualizarte con lo último de melanoma? Escúchame en @sciencelinkonco y Spotify
Kristel Gonzalez retweeted
Proud of the fact that we have avoided a ‘manel’. Nearly one third of our speakers are women. @cspramesh
Organizing the inaugural cancerconclave.com in Kerala. We have lined up an interesting array of topics on cancer care and control. #AMPOK
Join us on livestream. Link to follow.
Kristel Gonzalez retweeted
Don’t miss Session 3 at #APGCS2025: Hepatobiliary Malignancies.
Debates, fireside chats & key updates on HCC & BTC treatment—incl. Y90 therapy, SIERRA & TOURMALINE trials.
📅 Aug 1–2 | Singapore
🔗 Register now: apgcs.com/register-for-apgcs…
#GIOncology #LiverCancer
Kristel Gonzalez retweeted
✨ Relacorilant + Nab‑Paclitaxel: A New Standard in Platinum‑Resistant OC! ✨
🎯 Objective: Boost survival in platinum‑resistant epithelial ovarian cancer by combining the selective glucocorticoid receptor antagonist relacorilant with weekly nab‑paclitaxel (ROSELLA, phase III).
✅ Inclusion Criteria:
- Adults with platinum‑resistant ovarian, peritoneal, or fallopian tube carcinoma
- ECOG 0–1, measurable disease, progression <6 months post‑platinum
- Prior taxanes, bevacizumab, and ≤3 systemic treatments
📊 Key Results:
1️⃣ Median PFS improved to 6.5 vs 5.5 months (HR 0.70; p=0.0076) via blinded review
2️⃣ Median OS increased to 16.0 vs 11.5 months (HR 0.69; p=0.0121)
3️⃣ At 12 months, survival was 60% vs 49%; objective response rate ~36.9% vs 30.1%
4️⃣ Safety Profile: Manageable despite more grade ≥3 AEs (74.5% vs 59.5%), similar when adjusted for exposure time.
🧠 Conclusion: This landmark phase III trial establishes relacorilant + nab‑paclitaxel as a promising new option, significantly improving PFS and OS in a hard‑to‑treat group. Safety is acceptable for widespread use.
#OvarianCancer #ROSELLA #Relacorilant #NabPaclitaxel #GynecologicOncology #CancerBreakthrough 💊🎯🙌
@ASCO @myESMO @OncoAlert @AndreaAnampaG @IshwariaMD @neerajaiims @tmprowell @UmbertoMalapel1 @SewantiLimaye @AnaVManana
@Kristel_GT @NazliDizman @katsuki_arima @VJOncology @DarcyBurbage
Kristel Gonzalez retweeted
✨ First FDA-Approved PD‑1 Combo for Anal Cancer! ✨📰
🎯 Objective:
Assess efficacy of retifanlimab‑dlwr (Zynyz®) with carboplatin + paclitaxel (1L) and as monotherapy (2L+) in locally recurrent/metastatic SCAC.
✅ Inclusion Criteria:
• Adults with inoperable locally recurrent or metastatic SCAC
• Chemo-naïve for combination arm; prior platinum exposure for monotherapy arm
📊 Key Findings:
1️⃣ Combo arm (POD1UM‑303): PFS improved to 9.3 mo vs 7.4 mo (HR 0.63; p=0.0006)
2️⃣ ORR: 56% with combo vs 44% without DOR ~14 mo vs ~7.2 mo
3️⃣ Monotherapy (POD1UM‑202): ORR 14%, median DOR 9.5 mo
4️⃣ Safety: No new signals; serious AEs reported in ~47% of combo patients
🧠 Conclusion:
Retifanlimab‑dlwr combo sets a new standard first-line therapy for advanced SCAC, with strong PFS/response benefits. Monotherapy offers a new option for platinum-refractory patients.
#AnalCancer #Retifanlimab #PD1 #Immunotherapy #SCAC #OncologyBreakthrough 💉🧬🚀
@UmbertoMalapel1 @SewantiLimaye @AnaVManana
@Kristel_GT @NazliDizman @katsuki_arima @VJOncology @DarcyBurbage @manjuggm @MHuynhLe @EileenMOReilly @DenboJw @NiuSanford @YJanjigianMD @JTrentMDPhD @GIcancerDoc




































